Development and evaluation of lecithin-based andrographolide liposomal nanoparticles: pharmacokinetics and anti-inflammatory activity in a mouse model of house dust mite-induced allergic lung inflammation
Journal of Pharmacy and Pharmacology · 2026
DOI: 10.1093/jpp/rgag099 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2026. Verfasst von Emmanuel Oshiogwe Okwuofu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacotherapeutic Unit, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, 43400 Selangor, Malays…. Hauptthemen laut MEDLINE: Lecithins, Anti-Inflammatory Agents, Nanoparticles, Pyroglyphidae. Die Arbeit nennt 67 Literaturangaben. Gefördert von: Ministry of Agriculture and Agro-Based Industry, Malaysia.
Abstract (Originalsprache)
Objectives
This study aimed to develop, characterize, and evaluate the efficacy of a soy lecithin-based formulation of AGP (Lipo-AGP) in Balb/c.
Methods
Lipo-AGP was formulated using thin-film hydration. The formulation was characterized, followed by pharmacokinetic evaluation. A 14-day house dust mite (HDM)-induced lung inflammation model in BALB/c mice was used, comprising sensitization and challenge phases. Bronchoalveolar lavage (BAL) fluid cell analysis, cytokine assays, gene expression, lung histology, serum HDM-specific IgE, and immunoblotting were evaluated. Key findings The optimized Lipo-AGP formulation demonstrated a vesicle size of 178.9 ± 20.78 nm, a zeta potential of −27.73 ± 1.02 mV, and a PDI of 0.28 ± 0.001, alongside a high entrapment efficiency of 95.67 ± 1.78%. Stability analysis at 4°C and 25°C for 6 months did not show degradation. In vivo pharmacokinetics studies revealed that Lipo-AGP achieved a 1.5-fold improvement in both the rate and extent of AGP absorption compared to free AGP. Lipo-AGP exhibited a dose-dependent decrease in HDM-induced pulmonary cell infiltration, mucus hypersecretion, collagen deposition, and inhibition of nuclear NF-κB p65. These results suggest that Lipo-AGP exerts protective effects against HDM-induced lung inflammation, through inhibition of NF-κB signalling.
Conclusions
Liposomal nanocarrier represents a potential strategy to deliver the lipophilic compounds, AGP for improved pharmacokinetics profile and efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacotherapeutic Unit, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, 43400 Selangor, Malaysia.
- Department of Medicinal Chemistry, Faculty of Pharmacy, MAHSA University, Jenjarom, 42610 Selangor, Malaysia.
ORCID-Profile: Johnson Stanslas
Förderung
- Ministry of Agriculture and Agro-Based Industry, Malaysia
Zitieren
APA
Okwuofu, E. O., Yong, A. C. H., Lim, J. C. W., & Stanslas, J. (2026). Development and evaluation of lecithin-based andrographolide liposomal nanoparticles: pharmacokinetics and anti-inflammatory activity in a mouse model of house dust mite-induced allergic lung inflammation. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgag099
Vancouver
Okwuofu EO, Yong ACH, Lim JCW, Stanslas J. Development and evaluation of lecithin-based andrographolide liposomal nanoparticles: pharmacokinetics and anti-inflammatory activity in a mouse model of house dust mite-induced allergic lung inflammation. Journal of Pharmacy and Pharmacology. 2026. doi:10.1093/jpp/rgag099
BibTeX
@article{Okwuofu2026,
author = {Okwuofu, Emmanuel Oshiogwe and Yong, Audrey Chee Hui and Lim, Jonathan Chee Woei and Stanslas, Johnson},
title = {Development and evaluation of lecithin-based andrographolide liposomal nanoparticles: pharmacokinetics and anti-inflammatory activity in a mouse model of house dust mite-induced allergic lung inflammation},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
doi = {10.1093/jpp/rgag099}
}
EUVIMED